Anthem Biosciences Limited Stock Price Today (NSE: ANTHEM)
Fundamental Score
Anthem Biosciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Anthem Biosciences Limited share price today is ₹656.25, up +5.12% on NSE/BSE as of 30 March 2026. Anthem Biosciences Limited (ANTHEM) is a Large-cap company in the Biotechnology sector with a market capitalisation of ₹37.01K (Cr). The 52-week high for ANTHEM share price is ₹873.50 and the 52-week low is ₹579.15. At a P/E ratio of 79.93x, ANTHEM is currently trading above its industry average P/E of 51.82x. The company has a Return on Equity (ROE) of 20.83% and a debt-to-equity ratio of 0.04.
Anthem Biosciences Limited Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Anthem Biosciences Limited Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Anthem Biosciences Share Price: A ROCE-Focused Analysis
The biotechnology sector is experiencing a surge in demand for specialized research and manufacturing services, driven by the increasing complexity of drug development. This creates significant opportunities for Contract Research and Manufacturing Organizations (CRMOs) like Anthem Biosciences. This financial analysis, part of an 80-parameter fundamental audit verified by Sweta Mishra, examines the factors influencing the Anthem Biosciences share price, specifically focusing on Return on Capital Employed (ROCE).
Currently, the Anthem Biosciences share price is ₹652.9000244140625. The company exhibits a Price-to-Earnings (PE) ratio of 79.93 and a ROCE of 28.5%. While the PE ratio suggests a premium valuation, the ROCE offers deeper insight. A ROCE of 28.5% indicates that for every ₹100 of capital employed, Anthem Biosciences generates ₹28.5 in earnings. This level of efficiency suggests strong profitability and effective capital allocation. A consistently high ROCE, maintained over several years, can contribute significantly to building a durable economic moat, making it harder for competitors to erode the company's profitability.
Comparatively, evaluating Anthem Biosciences against its sector peers provides context. While detailed management quality assessments are beyond the scope of this analysis, a comparison with companies like
Advanced Enzyme Technologies Ltd regarding capital allocation strategies might be insightful. Exploring how Anthem Biosciences' management allocates capital compared to peers like Advanced Enzyme Technologies could reveal strengths or weaknesses in their operational efficiency. This analysis is not a comment on either company's management team.The 28.5% ROCE has several implications. Firstly, it suggests that Anthem Biosciences is effectively utilizing its assets to generate profits. Secondly, a higher ROCE generally leads to higher reinvestment rates, enabling the company to fund future growth and expansion projects. Finally, a sustained high ROCE signals competitive advantages and potential for long-term value creation. Further investigation into the sustainability of this ROCE, including industry trends and competitive pressures, would be beneficial. This analysis is purely observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Anthem Biosciences Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ANTHEM across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (20.83%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (28.50%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (38.78%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (23.86% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (37.27% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (63.42x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹576.31 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (74.69%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 79.93x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-40.74% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Limited Institutional Interest (FII+DII: 8.87%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Anthem Biosciences Limited Financial Statements
Comprehensive financial data for Anthem Biosciences Limited including income statement, balance sheet and cash flow
About ANTHEM (Anthem Biosciences Limited)
Anthem Biosciences Limited is a dynamic and innovative biotechnology company dedicated to accelerating scientific discovery and delivering impactful solutions across the pharmaceut...ical and life sciences industries. At the core of Anthem's operations lies a deep commitment to fostering collaborative partnerships with clients, offering a comprehensive suite of services designed to streamline the drug development process from inception to commercialization. Anthem distinguishes itself through its cutting-edge technological capabilities, seamlessly integrating advanced analytical techniques, bioinformatics, and process development strategies to optimize research outcomes and drive efficiency. The company's unwavering focus on quality, combined with its agile and client-centric approach, positions it as a trusted partner for organizations seeking to navigate the complexities of modern drug development and biomanufacturing. Anthem Biosciences operates through a dual-faceted approach, encompassing both comprehensive CRDMO services and the production of specialized ingredients. The CRDMO arm provides end-to-end support for both novel chemical entities (NCEs) and novel biological entities (NBEs), guiding projects through every stage of the pipeline. From the initial spark of target identification and proof-of-concept studies to rigorous preclinical development and the production of development batches for clinical trials, Anthem offers a seamless and integrated experience. This holistic approach allows clients to benefit from streamlined communication, reduced timelines, and enhanced control over the entire development process. Moreover, Anthem's expertise in specialty ingredient manufacturing ensures the availability of high-quality raw materials and key components critical for successful drug formulation and production. Beyond its core service offerings, Anthem Biosciences is driven by a vision to push the boundaries of biotechnological innovation. The company fosters a culture of scientific excellence, attracting top talent and investing heavily in research and development. Anthem's commitment to sustainability is evident in its environmentally conscious practices and dedication to responsible manufacturing. By embracing cutting-edge technologies and fostering a collaborative ecosystem, Anthem Biosciences is poised to play a significant role in shaping the future of healthcare. With a steadfast commitment to delivering exceptional value and driving scientific breakthroughs, Anthem Biosciences is truly at the forefront of the biotechnology revolution.
Company Details
Key Leadership
Latest News
ANTHEM Share Price: Frequently Asked Questions
What is the current share price of Anthem Biosciences Limited (ANTHEM)?
As of 30 Mar 2026, 12:06 pm IST, Anthem Biosciences Limited share price is ₹656.25. The ANTHEM stock has a market capitalisation of ₹37.01K (Cr) on NSE/BSE.
Is ANTHEM share price Overvalued or Undervalued?
ANTHEM share price is currently trading at a P/E ratio of 79.93x, compared to the industry average of 51.82x. Based on this relative valuation, the Anthem Biosciences Limited stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of ANTHEM share price?
The 52-week high of ANTHEM share price is ₹873.50 and the 52-week low is ₹579.15. These values are updated daily from NSE/BSE price data.
What factors affect the Anthem Biosciences Limited share price?
Key factors influencing ANTHEM share price include quarterly earnings growth (Sales Growth: 4.78%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Anthem Biosciences Limited a good stock for long-term investment?
Anthem Biosciences Limited shows a 5-year Profit Growth of 37.27% and an ROE of 20.83%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.04 before investing in ANTHEM shares.
How does Anthem Biosciences Limited compare with its industry peers?
Anthem Biosciences Limited competes with major peers in the Biotechnology. Investors should compare ANTHEM share price P/E of 79.93x and ROE of 20.83% against the industry averages to determine competitive standing.
What is the P/E ratio of ANTHEM and what does it mean?
ANTHEM share price has a P/E ratio of 79.93x compared to the industry average of 51.82x. Investors pay ₹80 for every ₹1 of annual earnings.
How is ANTHEM performing according to Bull Run's analysis?
ANTHEM has a Bull Run fundamental score of 63.7/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ANTHEM belong to?
ANTHEM operates in the Biotechnology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Anthem Biosciences Limited share price.
What is Return on Equity (ROE) and why is it important for ANTHEM?
ANTHEM has an ROE of 20.83%, which indicates excellent management efficiency. ROE measures how efficiently Anthem Biosciences Limited generates profits from shareholders capital.
How is ANTHEM debt-to-equity ratio and what does it indicate?
ANTHEM has a debt-to-equity ratio of 0.04, which indicates conservative financing with low financial risk.
What is ANTHEM dividend yield and is it a good dividend stock?
ANTHEM offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Anthem Biosciences Limited shares.
How has ANTHEM share price grown over the past 5 years?
ANTHEM has achieved 5-year growth rates of: Sales Growth 23.86%, Profit Growth 37.27%, and EPS Growth -40.74%.
What is the promoter holding in ANTHEM and why does it matter?
Promoters hold 74.69% of ANTHEM shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Anthem Biosciences Limited.
What is ANTHEM market capitalisation category?
ANTHEM has a market capitalisation of ₹37009 crores, placing it in the Large-cap category.
How volatile is ANTHEM stock?
ANTHEM has a beta of N/A. A beta > 1 suggests the Anthem Biosciences Limited stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ANTHEM operating profit margin trend?
ANTHEM has a 5-year average Operating Profit Margin (OPM) of 38.78%, indicating the company's operational efficiency.
How is ANTHEM quarterly performance?
Recent quarterly performance shows Anthem Biosciences Limited YoY Sales Growth of 4.78% and YoY Profit Growth of 7.10%.
What is the institutional holding pattern in ANTHEM?
ANTHEM has FII holding of 1.66% and DII holding of 7.21%. Significant institutional holding often suggests professional confidence in the Anthem Biosciences Limited stock.